CaMKK2 Inibitors: Quinoline Analogs

In my last post, I reported a new synthetic route to our quinoline series, Scheme 1. The goal was to overcome prior synthetic challenges and to allow for rapid synthesis of many different analogs over a short period of time. Scheme 1: New synthetic route for generating quinoline analogs I have as a result generated large Read More …

Synthesis of promiscuous ALK2 inhibitors-continuation-2

Continuing with our goal to synthesize three compounds as ALK2 inhibitors, let’s refer back to Scheme 2 in the previous post on this topic, compounds 6, 8 and 9 were synthesized in good yields (65-90%), however compound 10 could not be obtained.   Different conditions were tested to induce the cyclization of the bromo-pyrazine-2-carboxamide 9 Read More …

How many cells in DIPG behave like stem cells?

Stem cells are a set of cells that, unlike most cells in the body, can divide as many times as they want, and can turn into any cell in the body. The mutations in cancer often make the cells behave more like stem cells, because in order to grow into a large tumour they may Read More …

Growing co-crystallized fragments to ligands of the transcription factor brachyury (T)

In order to develop ligands addressing different possible binding sites of the transcription factor brachyury, fragments co-crystallized with this protein should be developed into ligands by using the program SparkTM (Cresset®). Brachyury (T, TBXT) is an essential regulator of the notochord development. Brachyury is primarily expressed in the embryo but not in the majority of normal Read More …

Novel Hinge Binders: N-Methyl-azaindoles

One goal of the CaMKK2 project is to explore the chemistry and biology of novel hinge binders. Various hinge binders showing CaMKK2 inhibition have been identified in the literature and through testing of compounds synthesized in the SGC. Of note in this search was a recent publication by Price et al. (Bioorg. Med. Chem. Lett., Read More …

Synthesis of promiscuous ALK2 inhibitors

In a collaboration between SGC-University of North Carolina-Chapel Hill and M4K Pharma, we plan to synthesize 3 different imidazopyridin pyrazines as promiscuous kinase ALK2 inhibitors, compounds 1-3, Scheme 1. The first step will be the synthesis of key intermediate 10, Scheme 2.  The proposed synthesis begins with a nucleophilic aromatic substitution on compound 4 to Read More …

Checking I haven’t got my cells mixed up…

Did you know as many as 30% of the cells in labs could be misidentified? And what a nightmare it would be to find out years of your work are just completely wrong because you got your skin cells mixed up with your brain cells… So to avoid that catastrophe, I took some time to Read More …

Quinoline Series: Synthesis

We have received some very interesting biological data for our CaMKK2 inhibitor series (furopyridine, Azaindole and quinoline) and I will be sharing the data in the coming weeks, but before that, I wanted to share my synthetic efforts towards our quinoline series. Initial synthesis of quinoline analogs: Starting with 6-Bromo-4-chloroquinoline, a two (2) step synthetic Read More …

Optimising seeding of normal and FOP cells for a later assay – prettier than expected

Further down the line I want to be able to test the activation of the BMP signalling pathway downstream of the ALK2 receptor. For this I plan to use the alkaline phosphatase gene as a readout – it’s a well known gene activated downstream of BMP signalling so a lot of easy to use assays Read More …

Selective CDKL2 inhibitors – molecular modeling

At SGC we are interested in developing protein kinase inhibitors with a high selectivity towards other protein kinases. Based on lead compounds from the literature and our group new and selective CDKL2 inhibitors should be designed, synthesized and tested. Carla Alamillo, a former member of our group, worked on this topic and mentioned in her Read More …